Prescription medicine
Lanadelumab Brand names: Takhzyro
Lanadelumab (Takhzyro) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the lanadelumab FDA label on DailyMed (effective August 26, 2026); every lanadelumab label on DailyMed.
Highlights of the record
FDA label of August 26, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageTAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.
Forms and strengths
- 150 mg/ml
- 300 mg/2ml
Solution.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is lanadelumab used for?
From the label: indications and usageTAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older.
FDA pharmacologic class: Plasma Kallikrein Inhibitor.
Source: FDA drug label (TAKHZYRO), Takeda Pharmaceuticals America, Inc., effective August 26, 2026 (SPL set 15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8), via openFDA; the full label on DailyMed
Is there a generic for lanadelumab (Takhzyro)?
No generic lanadelumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the lanadelumab label say about other medicines?
The lanadelumab label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Heparin | drug interactions | Only one patient in the 300 mg every 2 weeks (q2wks) treatment group experienced transient aPTT prolongation ≥1.5x ULN which was confounded by ongoing heparin therapy. |
Source: FDA drug label (TAKHZYRO), Takeda Pharmaceuticals America, Inc., effective August 26, 2026 (SPL set 15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8), via openFDA; the full label on DailyMed
What next?
- Other plasma kallikrein inhibitors
- the pharmacologic class, with prices and generics
- Check an interaction
- what two or more labels say about each other